Skip to content

Lyra Direct Strep Assay

by Quidel Corporation

De Novo DEN140005

Lyra Direct Strep Assay is a medical device (FDA Class II; FDA product code PGX, Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System) made by Quidel Corporation, granted FDA De Novo DEN140005 on 16 Apr 2014, active as of 10 Oct 2026.

Active United States

De Novo

Valid until

No expiry

De Novo grant is not time-limited

FDA recalls

None found

in data synced 10 Oct 2026

Documents

Trust

Unverified

Source FDA De Novo, synced 10 Oct 2026.

Regulatory status

as of registry sync 10 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA De NovoDENG De Novo granted · Post-NSE NumberDEN140005 Date16 Apr 2014DecidedStatusActive

Official records

From the FDA record

Received by the FDA
25 Mar 2014
FDA decision
16 Apr 2014
FDA review time
22 days from receipt to decision

From the FDA De Novo record DEN140005 (openFDA), as read on 10 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA De Novo Active

Specification

De Novo

De Novo Number
FDA product code
PGX
Device class
Class II
Regulation
21 CFR Part 866.2680
Advisory committee
Microbiology
FDA decision
DENG De Novo granted

Similar devices

Other devices filed under FDA product code PGX (Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System).

Other devices from Quidel Corp.

See all devices from Quidel Corp. →